Supplementary Table from The PD-L1/4-1BB Bispecific Antibody–Anticalin Fusion Protein PRS-344/S095012 Elicits Strong T-Cell Stimulation in a Tumor-Localized Manner
Janet K. Peper-Gabriel, Shane A. Olwill(Pieris Pharmaceuticals (United States)), Alix Scholer‐Dahirel(Servier (France)), Matthieu Rivière(Servier (France)), Rachida S. Bel Aiba, Birgit Bossenmaier(Roche Pharma AG (Germany)), Aizea Morales‐Kastresana, Celine Sancerne, Markus Zettl, Eva-Maria Hansbauer(Pieris Pharmaceuticals (United States)), Thomas J. Jaquin(Pieris Pharmaceuticals (United States)), Maximilien Grandclaudon, Lucia Pattarini(Servier (France)), Catherine Gallou, Marleen Richter(Pieris Pharmaceuticals (United States)), Véronique Blanc(Imperial College London), Christine Rothe, Hélène Lelièvre, Marina Pavlidou(Pieris Pharmaceuticals (United States))
Cited by 1
Related Papers
Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice
|Proceedings of the National Academy of Sciences|2006|1k
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer
|PLoS ONE|2017|54
The phosphopantetheinyl transferase KirP activates the ACP and PCP domains of the kirromycin NRPS/PKS of Streptomyces collinus Tü 365
|FEMS Microbiology Letters|2011|24
Preclinical concept studies showing advantage of an inhaled anti-CTGF/CCN2 protein for pulmonary fibrosis treatment
|Nature Communications|2025|13
Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains
|Frontiers in Pharmacology|2021|11